REGENERATE: A Phase 3 International, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH

被引：0
|
作者：
Younossi, Zobair [1 ]
Ratziu, Vlad [2 ]
Dufour, Jean-Francois [3 ]
MacConell, Leigh [4 ]
Shringarpure, Reshma [4 ]
Harrison, Stephen [5 ,6 ]
Sanyal, Arun J. [6 ]
机构：
[1] Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA
[2] Sorbonne Univ, Hop Pitie Salpetriere, Paris, France
[3] Univ Bern, Bern, Switzerland
[4] Intercept Pharmaceut, San Diego, CA USA
[5] Pinnacle Clin Res Ctr, San Antonio, TX USA
[6] Virginia Commonwealth Univ, Richmond, VA USA
来源：
SWISS MEDICAL WEEKLY | 2019年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H34
引用
收藏
页码：27S / 27S
页数：1
相关论文
共 50 条
  • [21] OBETICHOLIC ACID (OCA) IMPROVES NON-INVASIVE MARKERS OF FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH): A SECONDARY ANALYSIS OF THE PHASE 3 REGENERATE STUDY
    Anstee, Q. M.
    Harrison, S.
    Sanyal, A. J.
    Ratziu, V.
    Rinella, M.
    Younossi, Z. Y.
    Boursier, J.
    Francque, S.
    Geerts, A.
    Petta, S.
    Bugianesi, E.
    Romero-Gomez, M.
    Schattenberg, J. M.
    Sarkar, S.
    Bonacini, M.
    Yataco, M.
    Porayko, M.
    Siddique, A.
    Dufour, J.
    Ferro, T.
    Venugopal, A.
    Zaru, L.
    Shringarpure, R.
    Macconell, L.
    Goodman, Z.
    Loomba, R.
    DIGESTIVE AND LIVER DISEASE, 2020, 52 : S163 - S163
  • [22] OBETICHOLIC ACID (OCA) IMPROVES NON-INVASIVE MARKERS OF FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH): A SECONDARY ANALYSIS OF THE PHASE 3 REGENERATE STUDY
    Anstee, Quentin M.
    Harrison, Stephen A.
    Sanyal, Arun J.
    Ratziu, Vlad
    Rinella, Mary E.
    Younossi, Zobair M.
    Boursier, Jerome
    Francque, Sven M.
    Geerts, Anja
    Petta, Salvatore
    Bugianesi, Elisabetta
    Romero-Gomez, Manuel
    Schattenberg, Joern
    Sarkar, Souvik
    Bonacini, Maurizio
    Yataco, Maria Luisa
    Porayko, Michael K.
    Siddique, Asma
    Dufour, Jean-Francois
    Ferro, Tom
    Venugopal, Aditya
    Zaru, Luna
    Shringarpure, Reshma
    MacConell, Leigh
    Goodman, Zachary D.
    Loomba, Rohit
    HEPATOLOGY, 2019, 70 : 1030A - 1032A
  • [23] Control: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Patients with Nonalcoholic Steatohepatitis
    Pockros, Paul J.
    Fuchs, Michael
    Freilich, Bradley L.
    Schiff, Eugene R.
    Kohli, Anita
    Lawitz, Eric J.
    Hellstern, Paul A.
    Cohen, David E.
    Owens-Grillo, Janet
    Van Biene, Courtney
    Shringarpure, Reshma
    MacConell, Leigh
    Shapiro, David A.
    HEPATOLOGY, 2018, 68 : 951A - 952A
  • [24] Evaluation of non-invasive tests to identify precirrhotic fibrosis due to NASH in patients screened for the phase 3 REGENERATE and REVERSE studies of obeticholic acid
    Loomba, Rohit
    Kowdley, Kris
    Anstee, Quentin
    Noureddin, Mazen
    Younossi, Zobair
    Alkhouri, Naim
    Boursier, Jerome
    Harrison, Stephen
    Capozza, Thomas
    Li, Jing
    Gasink, Christopher
    Rinella, Mary
    JOURNAL OF HEPATOLOGY, 2023, 78 : S118 - S118
  • [25] Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (vol 394, pg 2184, 2019)
    Younossi, Z. M.
    Ratziu, V
    Loomba, R.
    LANCET, 2020, 396 (10247): : 312 - 312
  • [26] Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study
    Lortholary, Olivier
    Chandesris, Marie Olivia
    Livideanu, Cristina Bulai
    Paul, Carle
    Guillet, Gerard
    Jassem, Ewa
    Niedoszytko, Marek
    Barete, Stephane
    Verstovsek, Srdan
    Grattan, Clive
    Damaj, Gandhi
    Canioni, Danielle
    Fraitag, Sylvie
    Lhermitte, Ludovic
    Georgin-Lavialle, Sophie
    Frenzel, Laurent
    Afrin, Lawrence B.
    Hanssens, Katia
    Agopian, Julie
    Gaillard, Raphael
    Kinet, Jean-Pierre
    Auclair, Christian
    Mansfield, Colin
    Moussy, Alain
    Dubreuil, Patrice
    Hermine, Olivier
    LANCET, 2017, 389 (10069): : 612 - 620
  • [27] Efficacy and safety of lubiprostone for the treatment of chronic idiopathic constipation: A phase 3, randomized, placebo-controlled study
    Coss-Adame, E.
    Remes-Troche, J. M.
    Rendon, R. Flores
    de la Cuesta, J. L. Tamayo
    Diaz, M. A. Valdovinos
    REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2024, 89 (01): : 70 - 79
  • [28] Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study
    Earley, Willie
    Burgess, Maria Victoria
    Rekeda, Ludmyla
    Dickinson, Regan
    Szatmari, Balazs
    Nemeth, Gyorgy
    McIntyre, Roger S.
    Sachs, Gary S.
    Yatham, Lakshmi N.
    AMERICAN JOURNAL OF PSYCHIATRY, 2019, 176 (06): : 439 - 448
  • [29] Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
    Goadsby, Peter J.
    Wietecha, Linda A.
    Dennehy, Ellen B.
    Kuca, Bernice
    Case, Michael G.
    Aurora, Sheena K.
    Gaul, Charly
    BRAIN, 2019, 142 : 1894 - 1904
  • [30] Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus
    van Vollenhoven, Ronald F.
    Kalunian, Kenneth C.
    Doerner, Thomas
    Hahn, Bevra H.
    Tanaka, Yoshiya
    Gordon, Robert M.
    Shu, Cathye
    Fei, Kaiyin
    Gao, Sheng
    Seridi, Loqmane
    Gallagher, Patrick
    Lo, Kim Hung
    Berry, Pamela
    Zuraw, Qing C.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (11) : 1556 - 1563
12345